Key Takeaways PacBio and EpiCypher partner to accelerate epigenomics with the Fiber-Seq workflow.The deal combines PacBio's HiFi sequencing with EpiCypher's chromatin expertise.Fiber-Seq links genetic and epigenetic data, streamlining assays into one workflow.PacBio (PACB) recently entered into a strategic partnership with EpiCypher to accelerate advancements in epigenomics research through the adoption of its Fiber-Seq workflow. This collaboration brings together PacBio’s long-read sequencing technology wi ...

Core Insights - PacBio has announced a partnership with EpiCypher to integrate EpiCypher's CUTANA Hia5 enzyme into its Fiber-seq assays, enhancing the ability to study chromatin biology at single-molecule resolution [1][3] - The collaboration aims to advance research in gene regulation, particularly in the context of rare diseases and cancer, by providing a comprehensive view of genetic and epigenetic features in a single assay [2][3] Company Overview - PacBio is a leading life science technology company focused on developing advanced sequencing solutions to address complex genetic problems across various research applications, including oncology and infectious diseases [4] - The company’s HiFi long-read sequencing technology is designed to provide high-quality data for a wide range of genomic studies [4] Product Details - The CUTANA Hia5 enzyme is now commercially available in 8 and 24 reaction formats, along with a supported Fiber-seq protocol, enabling researchers to generate insights into gene regulation [3] - Fiber-seq is an advanced multi-omic whole genome sequencing assay that measures chromatin accessibility, DNA methylation, and DNA variation simultaneously, offering a more integrated approach compared to traditional methods [2][3] Research Implications - The partnership is expected to facilitate the interrogation of complex genomic regions that are difficult to analyze with short-read approaches, potentially leading to breakthroughs in understanding rare diseases [7] - By consolidating multiple assays into a single workflow, researchers can save time and resources while obtaining richer data, which is crucial for advancing biological research [7]

Summary of Pacific Biosciences of California (PACB) FY Conference Call - August 12, 2025 Company Overview - **Company**: Pacific Biosciences of California (PACB) - **Conference Date**: August 12, 2025 - **Key Focus**: Discussion of Q2 results and future outlook Key Points Financial Performance - Q2 revenue reached **$39.8 million**, slightly exceeding expectations and aligning with internal forecasts [3] - **60%** of placements were with new customers, indicating strong demand for long-read sequencing technology [3] - **45% growth** in revenue from the rest of the world, particularly in EMEA and Asia Pacific [3] - Continued improvement in gross margins quarter over quarter, attributed to better yields from smart cells [3] Cash Flow and Guidance - Reduced cash burn in Q2, with expectations for further reductions in the second half of the year [4] - Targeting cash flow positivity by the end of **2027** [4] - Guidance range refined due to increased confidence in the second half of the year, despite uncertainties related to NIH funding and tariffs in China [9][10] Market Dynamics - EMEA anticipated to be the strongest growth region, with significant progress in PopGen studies and hospital collaborations [5] - Modest pull-ahead in orders from China, primarily for consumables, impacting revenue stability [6][7] - U.S. academic customers showed continued spending on consumables, but larger budget allocations remain uncertain [11] Product Insights - The **Revio** instrument is seen as a key driver for future financial performance, although sales to academic customers have been lower than expected [14][12] - The company is diversifying its customer base beyond academia, focusing on biopharma and clinical markets [18] - Anticipated launch of **multi-use smart cells** expected to lower costs per genome and improve gross margins [34][35] Clinical Market Expansion - Clinical business now accounts for **15%** of consumables, with potential for significant growth as labs adopt PacBio technology [25][26] - Revio's introduction has reduced the cost per genome to approximately **$500**, making it more competitive in clinical settings [29][46] - Future growth expected from partnerships with labs like GeneDx and Varyontics, although significant revenue contributions are not anticipated until later years [31][32] Strategic Focus - Emphasis on improving gross margins through better supply chain management and product offerings [51] - The company is pivoting towards consumables and multi-use products in response to a challenging macroeconomic environment [56][58] - Long-term vision includes leveraging AI and advanced data analytics to enhance the value of PacBio's sequencing data [59] Risks and Considerations - Ongoing uncertainties regarding U.S. academic funding and potential impacts on sales forecasts [10][12] - The need for clarity in the funding environment to drive future sales of high-value instruments like Revio [13] Conclusion Pacific Biosciences is navigating a complex market landscape with a focus on expanding its customer base, improving product offerings, and achieving cash flow positivity by 2027. The company is optimistic about its growth potential in clinical markets and the impact of new technologies on its financial performance.

Core Viewpoint - The company reports a 10% year-over-year revenue growth driven by HiFi sequencing technology, with strong international growth in APAC (+53%) and EMEA (+35%) regions, maintaining full-year revenue guidance of $155 million to $165 million, representing a midpoint growth of 1-7% [2] Financial Performance Analysis - Q2 revenue reached $39.8 million, reflecting a 7% quarter-over-quarter and 10% year-over-year increase [3] - Revenue breakdown: Instrument revenue at $14.2 million (down 4% YoY), Consumables at $18.9 million (up 11% YoY), and Service revenue at $6.7 million (up 57% YoY) [3] - Non-GAAP gross margin improved to 38.3%, exceeding expectations due to higher consumables profit margins [3] - Cash balance stands at $315 million, above expectations, with projected annual cash burn of $115 million, an improvement of $72 million YoY [3] Key Drivers - Revenue growth is primarily driven by international expansion (combined APAC/EMEA growth of 45%) and new customers for the Vega system (60% from new clients) [4] - Ongoing uncertainty in U.S. academic funding continues to suppress instrument demand, while consumables show resilience [4] - Cost optimization measures led to an 18% year-over-year reduction in operating expenses [4] Business Operations - The Revio system has a cumulative deployment of 297 units (15 new units in Q2), with 60% targeting new customers and one-third entering clinical laboratories [5] - The Vega system has a cumulative deployment of 73 units (38 new units in Q2), with 70% used for non-whole genome applications (e.g., microbiome sequencing) [5] - Consumables account for 15% of clinical revenue, with clients like Quest entering commercialization [5] Technological Innovation - The Spark chemical reagent has improved throughput by 33% and reduced sequencing costs, now covering 90% of operations [6] - Multi-purpose intelligent cells (in development) are expected to lower customer costs and enhance company gross margins [6] Market Expansion - Strong international growth includes rare disease research in Nordic hospitals and population sequencing projects in Southeast Asia [8] - Collaborative cases include Haorai Gene in China promoting transfusion medicine applications and Target ALS for global genomic research [8] Future Outlook and Planning - Short-term goals for 2025 include maintaining revenue guidance of $155 million to $165 million, with double-digit growth in consumables offsetting instrument declines [9] - Targeting non-GAAP gross margin improvement to 37-40% (with expectations to exceed 40% by year-end) and controlling operating expenses between $235 million and $240 million [9] Mid to Long-term Strategy - Aiming for positive cash flow by 2027 [10] - Plans to expand clinical and population genomics markets through HiFi technology and multi-omics solutions [10] CEO Insights - The CEO emphasizes the unique advantages of HiFi technology (long reads and simultaneous epigenetic detection) and aims to lower adoption barriers through innovation [11] - Reiterates financial discipline and focuses on clinical translation and scale effects, with a goal to become a leader in genomic medicine [11]

Core Insights - PacBio reported an adjusted loss per share of 13 cents for Q2 2025, an improvement from a loss of 20 cents per share in the previous year, exceeding the Zacks Consensus Estimate by 27.8% [1] - Total revenues for PacBio in Q2 2025 reached $39.8 million, reflecting a year-over-year increase of 10.4% and surpassing the Zacks Consensus Estimate by 9.1% [2] - The company updated its revenue outlook for 2025 to a range of $155 million to $165 million, compared to the previous guidance of $150 million to $170 million [13] Revenue Analysis - PacBio's total revenues were $39.8 million in Q2 2025, up 10.4% year over year, and exceeded estimates by 9.1% [2] - Revenue from the Americas was $17.7 million, down 15% year over year, attributed to government funding challenges [3] - The Asia-Pacific region saw revenues of $12.6 million, a significant increase of 53% year over year, driven by Revio and Vega placements [3] - EMEA region revenues improved by 35% year over year, totaling $9.5 million, supported by strong demand for Revio and Vega platforms [6] Segment Performance - Total product revenues were $33.1 million, a 4.2% increase from the previous year [7] - Instrument revenues decreased by 3.4% year over year to $14.2 million, primarily due to lower shipments of the Revio system [7] - Consumables revenues rose by 11.2% year over year to $18.9 million, with annualized Revio pull-through per system at $219,000 [8] - Service and other revenues surged by 57% year over year to $6.7 million, driven by increased service contract revenues related to Revio [8] Margin and Expense Trends - Adjusted gross profit increased by 15.1% year over year to $15.2 million, with adjusted gross margin expanding by 100 basis points to 38% [9] - Sales, general, and administrative expenses decreased by 21.2% year over year to $36.2 million, while research and development expenses fell by 41.5% to $22.5 million [9] - Total operating loss was $44.9 million, significantly reduced from $175.8 million in the prior year [10] Financial Position - PacBio ended Q2 2025 with cash and investments totaling $314.7 million, down from $343.1 million at the end of Q1 2025 [11] Strategic Developments - PacBio achieved a milestone with the publication of the Platinum Pedigree benchmark, enhancing the performance of AI-based variant calling tools [15] - The company joined the 1000 Genomes Long Read Project, contributing to isoform-level transcriptome sequencing [16] - A new distribution agreement with Haorui Gene aims to expand HiFi sequencing adoption in China [17]

Pacific Biosciences (PACB -8.70%), a life sciences company specializing in DNA sequencing technology, published its latest earnings results for the fiscal second quarter ended June 30, 2025, on August 7, 2025. The headline news was a revenue figure of $39.8 million (GAAP), which surpassed analyst expectations of $36.62 million. Losses per share (Non-GAAP EPS) were less than predicted at $(0.13), beating the non-GAAP loss of $(0.17) per share that analysts had forecast. Both top- and bottom-line results impr ...

Core Insights - Pacific Biosciences of California (PACB) reported revenue of $39.77 million for the quarter ended June 2025, marking a year-over-year increase of 10.4% and exceeding the Zacks Consensus Estimate by 9.06% [1] - The company posted an EPS of -$0.13, an improvement from -$0.20 a year ago, with a surprise of 27.78% compared to the consensus estimate of -$0.18 [1] Revenue Breakdown - Revenue from Product - Instrument was $14.15 million, slightly below the average estimate of $10.9 million, reflecting a year-over-year decline of 3.7% [4] - Revenue from Product was $33.08 million, surpassing the average estimate of $31.18 million, with a year-over-year increase of 4.2% [4] - Revenue from Service and other reached $6.68 million, significantly exceeding the estimated $5.09 million, representing a year-over-year increase of 56.6% [4] - Revenue from Product - Consumable was $18.93 million, below the average estimate of $20.29 million, but still showing a year-over-year growth of 11.4% [4] Stock Performance - Shares of Pacific Biosciences have declined by 6.8% over the past month, contrasting with a 1.2% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Company Performance - Pacific Biosciences reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.18, and an improvement from a loss of $0.20 per share a year ago, resulting in an earnings surprise of +27.78% [1] - The company posted revenues of $39.77 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 9.06% and showing an increase from $36.01 million in the same quarter last year [2] - Over the last four quarters, Pacific Biosciences has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Pacific Biosciences shares have declined approximately 24.6% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.16 on revenues of $40.08 million, and for the current fiscal year, it is -$0.64 on revenues of $155.44 million [7] Industry Outlook - The Medical - Instruments industry, to which Pacific Biosciences belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact the stock's performance [5]

Pacific Biosciences of California (PACB) Q2 2025 Earnings Call August 07, 2025 05:00 PM ET Speaker0Good afternoon, and welcome to the PacBio Second Quarter twenty twenty five Earnings Conference Call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. I would now like to turn the conference over to Todd Friedman, Director of Investor Relations. Please go ahead.Speaker1Good afternoon, and welcome to PacBio's second quarter twenty twenty fi ...

Financial Performance - Q2 2025 product and service revenue reached $39.8 million, a 7% sequential increase and a 10% increase compared to Q2 2024[12] - Consumable revenue increased by 11% year-over-year, with Revio pull-through in the low-to-mid $200,000s per system[12] - Instrument revenue increased sequentially but decreased by 4% year-over-year due to funding constraints[12] - Non-GAAP gross margin was approximately 38% in Q2 2025, compared to 37% in Q2 2024[45, 47] - Q2 2025 non-GAAP operating expenses were $58.1 million, an 18% decrease compared to Q2 2024[47] - Cash burn was approximately $28 million in Q2 2025, with expectations for improvement in the second half of the year[46] System Placements - 15 Revio systems were shipped in Q2 2025, with 60% going to new customers and one-third to Dx/LDT and hospital labs[12] - 38 Vega systems were shipped, with nearly 60% going to new customers[13] - Cumulative Revio shipments reached 297, and Vega shipments reached 73[14] Guidance - Full-year revenue guidance is maintained at the midpoint, narrowing the range to $155 million to $165 million, representing 1% to 7% growth over 2024[21, 22] - The company expects mid-teens growth in consumables revenue and a mid-teens decline in instrument revenue[22]